Turner, N. C., Seckl, M. J. (2010) A Therapeutic Target for Smoking-Associated Lung Cancer. Science Translational Medicine, 2 (62). ISSN 1946-6234

Full text not available from this repository.

Abstract

A report in this issue of Science Translational Medicine reveals that amplification of the FGFR1 gene-which encodes fibroblast growth factor receptor 1-is a major oncogenic aberration in squamous cell lung cancer. This genetic variation may represent the first relatively high-frequency therapeutic target of smoking-associated lung cancer.

Item Type:	Article
All Authors:	Turner, N. C., Seckl, M. J.
Additional Information:	ISI Document Delivery No.: 735UG Times Cited: 0 Cited Reference Count: 32 Turner, Nicholas C. Seckl, Michael J. Astra Zeneca N.C.T. is a consultant for Novartis and receives research funding from Astra Zeneca. Amer assoc advancement science Washington
Uncontrolled Keywords:	fibroblast-growth-factor polymorphism array analysis monoclonal-antibody breast-cancer fgfr1 amplifications tumors inhibition carcinomas expression
Research teams:	ICR divisions > Breast Cancer Research > Gene Function ICR divisions > Molecular Pathology > Gene Function
Depositing User:	Barry Jenkins
Date Deposited:	05 Apr 2011 12:07
Last Modified:	10 Aug 2011 13:59
URI:	http://publications.icr.ac.uk/id/eprint/10612

Actions (login required)

View Item